Stocktoria
CytomX Therapeutics, Inc. CTMX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-10-08
CytomX Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M |
| R&D expense | $68.7M | $83.4M | $77.7M | $111.6M | $114.2M |
| Operating income | -$22.4M | $25.0M | -$6.5M | -$101.3M | -$116.0M |
| Income tax | $238,000 | $224,000 | $3.9M | $0 | $0 |
| Net income | -$17.4M | $31.9M | -$569,000 | -$99.3M | -$115.9M |
| Operating cash flow | -$75.6M | -$86.2M | -$56.0M | -$110.8M | -$119.0M |
| Free cash flow | -$75.8M | -$86.5M | -$56.9M | -$112.5M | -$120.6M |
| Cash & equivalents | $12.7M | $38.1M | $17.2M | $193.7M | $205.5M |
| Total assets | $151.6M | $120.5M | $201.8M | $260.9M | $339.4M |
| Total liabilities | $52.6M | $121.0M | $249.2M | $346.6M | $339.9M |
| Shareholders' equity | $99.0M | -$456,000 | -$47.4M | -$85.8M | -$459,000 |
Source: SEC EDGAR filings · CIK 0001501989 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.